Theravance Biopharma Inc.

NASDAQ: TBPH · Real-Time Price · USD
13.14
0.20 (1.55%)
At close: Aug 15, 2025, 3:59 PM
13.15
0.08%
After-hours: Aug 15, 2025, 04:20 PM EDT

Theravance Biopharma Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
37.8M 39.55M 298.17M 89.96M
Short-Term Investments
50.55M 62.88M 29.31M 83.51M
Long-Term Investments
n/a n/a 836K 67.54M
Other Long-Term Assets
157.32M 203.1M 201.1M 4.07M
Receivables
68.44M 17.47M 16.79M 57.6M
Inventory
n/a n/a 1.51M 10.24M
Other Current Assets
4.2M 11.6M 7.68M 8.56M
Total Current Assets
161.07M 133.54M 353.46M 249.87M
Property-Plant & Equipment
35.77M 45.35M 52M 53.35M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
193.09M 248.46M 253.94M 124.95M
Total Assets
354.16M 382M 607.4M 374.82M
Account Payables
2.24M 1.52M 1.55M 3.1M
Deferred Revenue
n/a n/a 24K 98K
Short-Term Debt
n/a n/a n/a 16.94M
Other Current Liabilities
n/a 12.88M 10.07M 50.3M
Total Current Liabilities
32.09M 24.77M 28.71M 58.59M
Long-Term Debt
n/a n/a 45.41M 599.39M
Other Long-Term Liabilities
107.42M 99M 45.88M 2.42M
Total Long-Term Liabilities
146.53M 144.24M 136.88M 654.8M
Total Liabilities
178.62M 169M 165.6M 713.39M
Total Debt
49.82M 49.16M 74.12M 652.08M
Common Stock
n/a n/a 1K 1K
Retained Earnings
-965.52M -909.1M -853.91M -1.73B
Comprehensive Income
7K -65K -15K -0.00
Shareholders Equity
175.54M 213M 441.8M -338.57M
Total Investments
50.55M 62.88M 29.31M 151.04M